Barclays PLC Myriad Genetics Inc Put Options Transaction History

Barclays PLC

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2020 May 13, 2020	SELL	$9.78 - $29.53 $101,712 - $307,112	-10,400 Reduced 52.26%	9,500 $136,000
Q4 2019 Feb 10, 2020	BUY	$20.93 - $35.1 $4,186 - $7,020	200 Added 1.02%	19,900 $542,000
Q3 2019 Nov 14, 2019	SELL	$22.08 - $47.08 $1.19 Million - $2.55 Million	-54,100 Reduced 73.31%	19,700 $564,000
Q2 2019 Aug 14, 2019	SELL	$22.67 - $35.0 $446,599 - $689,500	-19,700 Reduced 21.07%	73,800 $2.05 Million
Q1 2019 May 15, 2019	BUY	$26.93 - $34.7 $2.46 Million - $3.17 Million	91,300 Added 4150.0%	93,500 $3.1 Million
Q4 2018 Feb 14, 2019	BUY	$27.23 - $45.56 $32,676 - $54,672	1,200 Added 120.0%	2,200 $64,000
Q2 2018 Aug 14, 2018	SELL	$27.75 - $40.17 $1.12 Million - $1.62 Million	-40,300 Reduced 97.58%	1,000 $37,000
Q1 2018 May 15, 2018	BUY	$28.83 - $41.01 $1.15 Million - $1.64 Million	39,900 Added 2850.0%	41,300 $1.22 Million
Q4 2017 Feb 14, 2018	SELL	$28.45 - $37.14 $290,190 - $378,828	-10,200 Reduced 87.93%	1,400 $48,000
Q3 2017 Nov 14, 2017	BUY	$24.01 - $36.2 $278,516 - $419,920	11,600	11,600 $420,000

253

90.9M

100K

34K

Ticker MYGN
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 80,634,800
Market Cap $1.23B
Description
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.